Toxicology – Clonidine

Core concept

Clonidine is a central α₂-adrenergic agonist that produces a characteristic sympatholytic, opioid-like toxidrome in overdose.

The classic syndrome is:

CNS depression + miosis + bradycardia ± hypotension + respiratory depression

A useful sequence is:

Central α₂ stimulation → ↓ sympathetic outflow → sedation + bradycardia + hypotension + hypoventilation

A distinctive additional feature is:

Early transient hypertension → later bradycardia/hypotension

because high clonidine concentrations can initially stimulate peripheral vascular α₂ receptors.

The main treatment is:

Supportive airway/ventilatory care + hemodynamic support

Naloxone is not a specific antidote, but modern pediatric evidence supports a trial—sometimes using substantially higher doses than standard opioid reversal doses—in significant CNS/respiratory depression.

Current Forms

Immediate-release tablets

Current U.S. clonidine hydrochloride tablets are available as:

• 0.1 mg
• 0.2 mg
• 0.3 mg

and remain indicated for hypertension. Current labeling notes commonly used therapeutic doses around 0.2–0.6 mg/day, with 2.4 mg/day described as the maximum effective daily dose, although such high doses are rarely used. (DailyMed⁠)

Extended-release clonidine

Extended-release clonidine is currently used for:

Attention-deficit/hyperactivity disorder (ADHD)

either:

• As monotherapy
• Or with stimulant medication

Current labeling establishes efficacy in children/adolescents:

6–17 years

and uses 0.1-mg extended-release tablets titrated gradually. (DailyMed⁠)

This is an important modernization because pediatric clonidine exposure now commonly occurs from medications prescribed directly to children for ADHD or behavioral disorders rather than solely from a grandparent’s antihypertensive medication. Pediatric poison-center data have shown increasing exposure over time. (PubMed⁠)

Transdermal Clonidine

Current Catapres-TTS systems deliver:

• 0.1 mg/day
• 0.2 mg/day
• 0.3 mg/day

for approximately 7 days. (DailyMed⁠)

Crucial toxicology point

The amount inside the patch is far greater than the nominal daily dose.

Current 2026 Catapres-TTS systems contain approximately:

• 0.1-mg/day patch → 3.09 mg total clonidine
• 0.2-mg/day patch → 6.19 mg
• 0.3-mg/day patch → 9.28 mg

(DailyMed⁠)

Therefore:

A swallowed or chewed clonidine patch is a potentially major overdose.

Even after normal use, a patch can still contain clinically important active drug. Current labeling specifically warns that used patches remain dangerous to infants and children and should be folded adhesive-side-to-adhesive-side and discarded securely. (DailyMed⁠)

Current Uses

Clonidine is currently used for:

• Hypertension
• ADHD
• Selected withdrawal syndromes
• Other specialist/off-label indications

Off-label uses may include:

• Opioid withdrawal
• Tic disorders
• Sleep-related/behavioral indications
• Selected autonomic hyperactivity syndromes

The old chapter’s emphasis on migraine, menopausal flushing, and dysmenorrhea is much less relevant to contemporary exposure patterns.

Toxic Dose

There is:

No single reliable toxic dose.

Children can develop significant toxicity from very small absolute quantities.

Current labeling still notes that:

As little as 0.1 mg has produced toxicity in a child. (DailyMed⁠)

A prospective poison-center study of children <12 years found:

• No coma, respiratory depression, or hypotension among reported ingestions <0.3 mg
• The lowest reported dose producing coma and respiratory depression was 0.3 mg ≈ 15 μg/kg

(PubMed⁠)

A more recent pediatric series found:

• No moderate/severe bradycardia or hypotension below 5 μg/kg
• Some severe hemodynamic effects occurred between 5–10 μg/kg

(PubMed⁠)

Important

These are observational risk ranges—not guaranteed safe cutoffs.

Dose histories after accidental ingestion are often inaccurate.

Thus:

A single 0.1-mg tablet can be clinically important in a small child.

Adults

Adults have survived extremely large overdoses.

Current labeling describes survival after ingestion of:

100 mg

with:

• Initial hypertension
• Subsequent hypotension
• Bradycardia
• Apnea
• Semicoma
• Ventricular ectopy

after intensive supportive treatment. (DailyMed⁠)

Therefore:

Dose alone does not reliably predict mortality.

Pathophysiology

Central α₂-Adrenergic Receptor Agonism

Clonidine stimulates α₂ receptors in the:

• Brainstem
• Medulla

producing:

↓ central sympathetic outflow

which results in:

• ↓ Heart rate
• ↓ Peripheral vascular resistance
• ↓ Blood pressure
• ↓ Sympathetic tone
• Sedation

Current labeling describes clonidine as reducing sympathetic outflow and thereby decreasing peripheral resistance, renal vascular resistance, heart rate, and blood pressure. (DailyMed⁠)

Imidazoline Effects

Clonidine is an imidazoline derivative, and stimulation of central imidazoline receptors probably also contributes to its hypotensive and sedative effects.

This helps explain why structurally related agents such as:

• Tetrahydrozoline
• Naphazoline
• Oxymetazoline

can produce clonidine-like poisoning when ingested.

Why Initial Hypertension Occurs

At high concentrations, clonidine can stimulate peripheral vascular α₂ receptors.

Therefore the early sequence may be:

Peripheral vasoconstriction → transient hypertension

followed by:

Dominant central sympatholysis → bradycardia + hypotension

Current labeling specifically describes:

Early hypertension followed by hypotension and bradycardia. (DailyMed⁠)

Why Naloxone Sometimes Works

The mechanism is uncertain.

Proposed explanations include clonidine-associated:

• Release of endogenous opioids
• Interaction with endogenous endorphin/enkephalin pathways
• Secondary modulation of opioid receptors

This is not established as the principal mechanism of clonidine toxicity.

It nevertheless provides a biologic rationale for the observation that some patients—particularly children—wake dramatically after naloxone. (PubMed Central (PMC)⁠)

Pharmacokinetics

Immediate-release oral clonidine has approximately:

70–80% bioavailability

with peak plasma concentrations generally within:

1–3 hours.

Its elimination half-life is approximately:

12–16 hours

in normal renal function. (DailyMed⁠)

Renal Impairment

Approximately:

40–60% of absorbed clonidine may be recovered unchanged in urine

within 24 hours.

In severe renal impairment, the half-life can increase to approximately:

41 hours

(DailyMed⁠)

Therefore:

Renal impairment can meaningfully prolong clonidine toxicity.

Clinical Features

Classic Toxidrome

The most characteristic findings are:

Sleepy + slow + small pupils

Specifically:

• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression
• Hypothermia

This can closely resemble opioid poisoning.

Neurologic

Possible manifestations include:

• Drowsiness
• Lethargy
• Somnolence
• Ataxia
• Hypotonia
• Hyporeflexia
• Confusion
• Stupor
• Coma

CNS depression is particularly prominent in children.

Current labeling notes that CNS depression appears more frequently in children than adults. (DailyMed⁠)

Pupils

Miosis is common

and reinforces the similarity to opioid toxicity.

However:

• Miosis is not universal
• Normal pupils do not exclude clonidine
• Pinpoint pupils do not prove an opioid exposure

Respiratory

Clonidine can cause:

• Bradypnea
• Shallow ventilation
• Hypoventilation
• Apnea

Respiratory depression is generally less profound than after a major potent-opioid overdose, but severe pediatric exposures can require mechanical ventilation.

Patients may appear more responsive during physical stimulation and then drift back into hypoventilation when left undisturbed.

Important

Do not rely on repeatedly stimulating the patient as respiratory treatment.

Use objective assessment:

• Respiratory rate
• Capnography when available
• Blood gas when appropriate
• Oxygenation
• Airway reflexes

and ventilate when necessary.

Cardiovascular

Bradycardia

Sinus bradycardia is extremely common.

Adult overdose data found bradycardia in approximately:

76%

with:

• Median onset ~2.5 hours
• Median duration ~20 hours
• Reported duration as long as ~83 hours

(PubMed⁠)

Importantly:

Bradycardia alone is often well tolerated.

Do not treat the monitor simply because the heart rate is low.

Treat if there is:

• Hypotension
• Altered perfusion
• Ischemia
• Syncope
• Shock

Hypotension

Hypotension may result from:

• Central sympatholysis
• Bradycardia
• Reduced vascular resistance

In a large adult overdose series, hypotension occurred in approximately:

24%

and was generally not profound. (PubMed⁠)

Severe shock is possible but uncommon in isolated adult clonidine poisoning.

Initial Hypertension

High-dose exposure may cause early:

Transient hypertension

Current adult data documented early hypertension particularly after large ingestions around 8–12 mg. (PubMed⁠)

It usually precedes the later sympatholytic phase.

Therefore:

Do not reflexively treat early hypertension with a long-acting antihypertensive.

Doing so may worsen the subsequent hypotensive phase.

Conduction Abnormalities

Large overdoses may occasionally produce:

• Sinus-node dysfunction
• Junctional rhythm
• AV block
• Other reversible conduction abnormalities

Serious malignant dysrhythmias are far less characteristic than profound bradycardia.

Hypothermia

Hypothermia may occur because of:

• CNS depression
• Reduced sympathetic activity
• Environmental exposure during prolonged sedation

Use passive/active rewarming according to severity.

Seizures

Seizures are:

Uncommon

and should prompt consideration of:

• Severe poisoning
• Hypoxia
• Coingestion
• Alternative diagnosis

Differential Diagnosis

The most important mimic is:

Opioid poisoning

because both may cause:

• CNS depression
• Miosis
• Respiratory depression

However, clonidine often produces more marked:

Bradycardia

and naloxone response is much less predictable.

Other α₂ / Imidazoline Toxicants

Consider:

• Guanfacine
• Tizanidine
• Dexmedetomidine
• Brimonidine
• Tetrahydrozoline
• Oxymetazoline
• Naphazoline
• Xylazine

Many can produce variations of:

CNS depression + bradycardia + hypotension + miosis

Other Differential Diagnoses

Also consider:

• Benzodiazepines
• Barbiturates
• Baclofen
• Ethanol
• GHB
• Antipsychotics
• β-blockers
• Calcium-channel blockers

and medical causes such as:

• Hypoglycemia
• Hypoxia
• Sepsis
• Hypothyroidism
• Stroke
• Intracranial hemorrhage
• Postictal state

Diagnosis

Diagnosis is primarily:

Clinical

based on:

Exposure history + characteristic sympatholytic/opioid-like syndrome

There is no routinely available bedside clonidine assay required for management.

Clonidine Serum Levels

Serum/plasma clonidine concentrations can be measured by specialized laboratories but are:

• Rarely rapidly available
• Not necessary for routine management
• Poorly suited to emergency decision-making

Therefore:

Treat the patient rather than a clonidine level.

Routine Drug Screens

Standard hospital urine toxicology screens generally:

Do not test specifically for clonidine.

A negative “drug screen” does not exclude clonidine poisoning.

Initial Investigations

Mild known exposure

A completely asymptomatic patient may require little testing beyond clinical observation.

Symptomatic patient

Obtain:

• Bedside glucose
• ECG
• Continuous cardiac monitoring

Consider:

• Electrolytes
• Bicarbonate
• BUN
• Creatinine

particularly with:

• Hypotension
• Significant bradycardia
• Altered consciousness
• Renal disease

Respiratory Assessment

For CNS or respiratory depression consider:

• Continuous pulse oximetry
• Capnography
• Venous/arterial blood gas if significant hypoventilation

Important

A patient receiving oxygen can maintain a normal SpO₂ despite significant CO₂ retention.

Capnography can therefore be more sensitive for evolving hypoventilation.

Intentional Overdose

Also consider:

• Acetaminophen concentration
• Salicylate concentration
• Pregnancy testing when clinically appropriate
• Additional testing guided by coingestants

Treatment

1. Airway and Ventilation

The cornerstone is:

Supportive care

Assess:

• Mental status
• Respiratory rate
• Airway reflexes
• Ventilation

Provide:

• Oxygen if hypoxemic
• Bag-mask ventilation if needed

Intubate for:

• Persistent apnea
• Severe hypoventilation
• Inability to protect airway
• Refractory coma

However, because naloxone can occasionally rapidly reverse clonidine-associated somnolence—particularly in children—a prompt naloxone trial can sometimes avoid unnecessary intubation provided ventilation is being safely maintained while it is given.

Do not delay airway support in a truly unstable patient.

Naloxone

Is Naloxone an Antidote?

Not reliably.

Clonidine’s primary mechanism is α₂ agonism, not opioid-receptor agonism.

Nevertheless:

Naloxone may reverse clonidine-induced CNS depression in some patients.

Current clonidine labeling continues to describe naloxone as a potentially useful adjunct for:

• Respiratory depression
• Hypotension
• Coma

while warning that paradoxical hypertension has occasionally occurred. (DailyMed⁠)

Pediatric High-Dose Naloxone Evidence

Older studies often concluded that naloxone was ineffective, but most used:

≤2 mg

which may be an inadequate trial.

A later pediatric cohort of 52 exposures found:

• 51 were somnolent
• Naloxone awakened 40/51
• Recurrent sedation in some responded to repeat naloxone
• 20 somnolent/bradycardic patients received 10 mg IV naloxone
• 13/20 awoke
• Hypotension resolved in 7/11
• No adverse events occurred even among patients receiving 10 mg

(PubMed⁠)

A 2025 poison-center review therefore recommends considering high-dose naloxone in significant clonidine-induced CNS depression. (Utah Poison Control⁠)

Practical Naloxone Approach

There is no universally validated regimen.

One contemporary poison-center approach uses:

Naloxone 0.1 mg/kg IV, maximum 2 mg per dose

repeated every:

1–2 minutes

with escalation toward a cumulative dose of approximately:

10 mg

if the clinical situation warrants it. (Utah Poison Control⁠)

Some pediatric patients in the published series received a:

10-mg IV bolus

without reported adverse events. (PubMed⁠)

Important

High-dose therapy is best supported in:

Children with significant pure clonidine toxicity who are opioid-naïve.

Consult a poison center/medical toxicologist when escalating to high-dose therapy.

Adults and Naloxone

Evidence is weaker.

In a series of 108 adult clonidine overdoses:

• 23 received naloxone
• Median total dose was only about 2 mg
• Only one had documented partial improvement in consciousness

(PubMed⁠)

This does not prove that higher doses cannot work in adults, but it reinforces that:

Naloxone response is inconsistent.

Do not repeatedly delay definitive airway management waiting for naloxone to work.

Opioid Dependence / Coingestion

If a patient is chronically opioid-dependent or has an opioid coingestion:

High-dose naloxone may precipitate acute withdrawal.

Therefore titrate according to:

• Ventilation
• Clinical context
• Likelihood of opioid dependence

Naloxone Endpoint

The goal is:

Improved ventilation and clinically useful arousal

not necessarily complete wakefulness.

Persistent isolated bradycardia after the patient wakes is common and usually does not require further naloxone merely to normalize the heart rate.

The pediatric naloxone series specifically found patients who became awake despite persistent bradycardia. (PubMed⁠)

Bradycardia

Most clonidine-associated bradycardia is:

Benign if perfusion and blood pressure are adequate.

Do not automatically treat an asymptomatic heart rate of 40–50/min in an otherwise perfusing adult.

Atropine

Use atropine for:

Clinically important bradycardia with hypotension or poor perfusion.

A contemporary adult ACLS regimen is:

Atropine 1 mg IV every 3–5 minutes

to a maximum of:

3 mg

if appropriate.

Pediatric therapy follows current PALS weight-based dosing.

Important limitation

The effect of atropine may be:

• Incomplete
• Transient

Recent pediatric data found only transient improvement in some patients given atropine. (PubMed⁠)

Pacing

Temporary pacing is:

Rarely required

because the bradycardia usually reflects central sympatholysis rather than irreversible conduction-system failure.

Consider pacing only for:

• Severe refractory symptomatic bradycardia
• High-grade AV block
• Persistent hemodynamic instability

after standard supportive therapies have failed.

Hypotension

First-line

Treat with:

Isotonic IV crystalloid

when clinically volume responsive.

Avoid unnecessary large fluid volumes simply because the blood pressure is mildly low.

Vasopressors

For persistent shock despite appropriate fluids:

Vasopressor therapy is appropriate.

There is no strong evidence establishing one uniquely superior agent for clonidine overdose.

A contemporary physiology-based approach is:

• Norepinephrine for persistent vasodilatory hypotension
• Epinephrine may be useful when substantial bradycardia/low cardiac output accompanies shock

The older rule that dopamine is the preferred clonidine vasopressor should not be treated as a modern standard.

Hypertension

Early clonidine-associated hypertension is often:

Transient

and frequently resolves as central sympatholytic effects predominate.

Therefore:

Do not treat an isolated transient elevated blood pressure unless there is severe hypertension with evidence of end-organ injury.

If therapy is genuinely required:

• Use a short-acting
• Titrated IV antihypertensive

under critical-care/toxicology guidance.

Avoid long-acting treatment because profound hypotension may follow.

Seizures

Treat toxin-induced seizures with:

Benzodiazepines first-line

Examples:

• Midazolam
• Lorazepam
• Diazepam

Refractory seizures:

• Phenobarbital
• Propofol in an intubated patient

Also correct:

• Hypoxia
• Hypoglycemia
• Electrolyte abnormalities

Gastrointestinal Decontamination

Do Not Induce Vomiting

Do not use ipecac or induced emesis.

CNS depression can develop rapidly.

Current labeling specifically advises against ipecac because of the rapid onset of CNS depression. (DailyMed⁠)

Activated Charcoal

Single-dose activated charcoal may be considered after a:

• Recent
• Potentially significant

tablet ingestion if:

• The patient is fully alert with intact airway reflexes

or:

• The airway has been protected

A typical poisoning dose is approximately:

1 g/kg, usually maximum ~50 g

in routine practice.

Critical point

Do not give charcoal to a progressively somnolent child with an unprotected airway.

The benefit of decontamination is secondary to airway safety.

Gastric Lavage

The current drug label still mentions gastric lavage after recent major ingestion, but modern toxicology practice has moved away from routine lavage.

Therefore:

Routine gastric lavage is not recommended.

It should only rarely be contemplated after an exceptionally large, immediately life-threatening, very recent ingestion with:

• Protected airway
• Appropriate expertise
• Poison-center/toxicology input

Extended-Release Tablets

Because extended-release clonidine is now widely used for ADHD, formulation matters.

Large intentional ER ingestions may:

• Delay absorption
• Prolong the clinical course

A patient with a major ER ingestion warrants longer monitoring than a patient with a reliably tiny immediate-release exposure.

Whole-bowel irrigation is not routine, but could occasionally be considered after a very large modified-release ingestion in an appropriate, stable patient because toxicology position statements allow selected use after potentially toxic sustained-release drug ingestions. (PubMed⁠)

Transdermal Exposure

If toxicity develops while patches are being worn:

Remove every clonidine patch immediately.

Current labeling notes that after patch removal:

• Plasma clonidine persists for approximately 8 hours
• Concentrations then decline slowly over several days

(DailyMed⁠)

Thus:

Removing the patch does not immediately terminate toxicity.

Patch Ingestion

This deserves special attention because the patch reservoir can contain milligram quantities of clonidine.

Current Catapres-TTS patches contain up to:

9.28 mg clonidine

in the largest system. (DailyMed⁠)

A patch that is:

• Chewed
• Sucked
• Swallowed

can therefore produce major toxicity.

Whole-Bowel Irrigation After Patch Ingestion

The current Catapres-TTS label states that:

Whole-bowel irrigation may be considered after patch ingestion. (DailyMed⁠)

However, modern WBI guidance emphasizes that:

WBI should not be performed routinely in poisoned patients.

Evidence that it improves outcomes is limited, and it is contraindicated with:

• Ileus
• Obstruction
• GI perforation
• Hemodynamic instability
• Unprotected airway

(PubMed⁠)

Therefore:

Known clonidine-patch ingestion → early poison-center/medical-toxicology consultation.

WBI is a selective option, not an automatic intervention.

Endoscopic Patch Removal

A 2025 toxicology case report described successful:

Upper-endoscopic removal of an intact clonidine patch from the stomach

approximately 5 hours after ingestion, potentially avoiding prolonged exposure and extended WBI. (Taylor & Francis Online⁠)

This is an emerging case-based strategy, not established routine therapy.

It may be considered when:

• A dangerous intact patch is known to be in the stomach
• Presentation is sufficiently early
• Endoscopy can be performed safely

after multidisciplinary toxicology/GI discussion.

Antidote

There is no proven specific antidote for clonidine poisoning.

Naloxone is best regarded as:

A potentially useful adjunct

rather than a definitive antidote. (DailyMed⁠)

Enhanced Elimination

Hemodialysis

Clonidine is:

Poorly removed by hemodialysis.

Current labeling states that only a minimal amount is removed during routine dialysis and that dialysis is unlikely to significantly enhance elimination. (DailyMed⁠)

Therefore:

Do not dialyze a patient merely to remove clonidine.

Dialysis should be used only for an unrelated conventional indication.

Multiple-Dose Activated Charcoal

There is no established role for:

Multiple-dose activated charcoal

for enhanced clonidine elimination.

Urinary Alkalinization / Forced Diuresis

There is no useful role for:

• Urinary alkalinization
• Forced diuresis

in clonidine poisoning.

Time Course

Immediate-release tablets

Current labeling states that overdose manifestations generally begin within:

30 minutes–2 hours

(DailyMed⁠)

Adult data found median onset of bradycardia somewhat later, approximately:

2.5 hours

with some patients developing it beyond 5 hours. (PubMed⁠)

Duration

Symptoms can be prolonged because clonidine’s elimination half-life is relatively long.

Adult bradycardia lasted a median of approximately:

20 hours

and occasionally persisted much longer. (PubMed⁠)

Severe overdose may therefore produce:

• Sedation
• Bradycardia
• Hypotension

for >24 hours.

Renal impairment can prolong toxicity even further.

Patch Exposure

Patch-related toxicity may have:

• Delayed absorption
• Prolonged absorption
• Prolonged symptoms

and after removal, circulating clonidine can persist for hours followed by a gradual decline over several days. (DailyMed⁠)

Observation

The old universal:

“4–6 hours then discharge”

rule requires nuance.

Immediate-release exposure

For a reliably small immediate-release ingestion, a patient who remains:

• Completely asymptomatic
• Normal mental status
• Normal respiratory status
• Hemodynamically stable
• Normal/reassuring ECG

through approximately 4–6 hours is unlikely to develop major delayed toxicity.

Older pediatric data found no subsequent deterioration more than 4 hours after presentation in children who had remained stable. (PubMed⁠)

Longer Observation Is Appropriate For

• Extended-release clonidine
• Patch ingestion
• Unknown dose
• Large intentional ingestion
• Renal impairment
• Coingestants
• Any symptoms

Therefore:

Disposition should be formulation- and symptom-specific rather than based on a single clock time.

Admission

Hospital admission is appropriate for:

• Persistent CNS depression
• Recurrent naloxone requirement
• Respiratory depression
• Apnea
• Hypotension
• Symptomatic bradycardia
• Significant conduction abnormality
• Large intentional overdose
• Significant ER exposure
• Patch ingestion

ICU

ICU-level care is appropriate for:

• Intubation/mechanical ventilation
• Recurrent apnea
• Severe coma
• Shock requiring vasopressors
• Clinically important conduction disturbance
• Severe coingestant toxicity

Important modernization

Not every patient with:

• Mild isolated bradycardia
• Mild somnolence

requires ICU admission.

Recent pediatric series show that many abnormalities are mild despite being common. (PubMed⁠)

Discharge

Discharge should require:

• Normal/baseline mental status
• Normal ventilation
• Stable blood pressure
• Clinically acceptable heart rate/perfusion
• No recurrent sedation
• No ongoing naloxone requirement
• Adequate observation for the specific formulation

Persistent mild bradycardia may not itself require hospitalization if:

• Patient is asymptomatic
• Perfusion is normal
• Other toxicity has resolved

Intentional overdose requires appropriate psychiatric/safety assessment.

Clonidine Withdrawal

An important issue not emphasized enough in older overdose chapters is:

Abrupt clonidine withdrawal can cause severe rebound sympathetic activity.

Symptoms may include:

• Anxiety
• Agitation
• Tremor
• Headache
• Tachycardia
• Severe rebound hypertension

Rare severe complications include:

• Hypertensive encephalopathy
• Cerebrovascular events
• Death

Current labeling specifically warns against abrupt cessation. (DailyMed⁠)

Why This Matters in Toxicology

After a patient with chronic clonidine use recovers from an overdose, clonidine therapy should not necessarily be withheld indefinitely without a plan.

When clinically safe:

Restart/taper decisions should account for withdrawal risk.

Otherwise the patient can transition from:

Clonidine toxicity → clonidine withdrawal hypertension

Pregnancy

The old FDA Pregnancy Category C system is obsolete.

Current extended-release labeling states that several decades of published human experience have not identified a clonidine-associated increased risk of major congenital malformations, miscarriage, or other major adverse maternal/fetal outcomes. (DailyMed⁠)

In overdose:

Maternal airway, ventilation, perfusion, and blood pressure take priority.

Clonidine crosses the placenta, so significant maternal poisoning may also affect the fetus.

Breastfeeding

Clonidine is present in human milk.

Current extended-release labeling reports a relative infant dose around:

4.1–8.4% of the maternal weight-adjusted dose.

Most reported infants have had no adverse effects, but there is a case report of:

• Sedation
• Hypotonia
• Apnea

in an exposed infant. (DailyMed⁠)

Breastfed infants exposed to maternal clonidine should therefore be monitored for:

• Excess sedation
• Lethargy
• Poor feeding
• Hypotonia
• Respiratory depression
• Bradycardia/hypotension

Prognosis

Most patients recover fully with supportive care.

A large adult series of 108 acute overdoses reported:

• Frequent CNS depression
• Bradycardia in 76%
• Hypotension in 24%
• No deaths
• No significant malignant dysrhythmias

(PubMed⁠)

Serious morbidity is more likely from:

• Respiratory failure
• Prolonged hypoxia
• Large pediatric exposure
• Patch ingestion
• Coingestants

than from the bradycardia itself.

Prevention

Clonidine deserves particular caution in households with children.

Tablets

Store:

• Locked
• Out of sight/reach
• In child-resistant containers

A single 0.1-mg tablet can cause symptoms in a small child. (DailyMed⁠)

Patches

Both:

Used AND unused patches remain dangerous.

Current instructions state that after use, patches should be:

Folded in half with sticky sides together

and discarded carefully out of children’s reach. (DailyMed⁠)

Never assume a “used” patch is pharmacologically empty.

Important Pitfalls

1. Mistaking clonidine poisoning for opioid overdose

Both may produce:

Coma + miosis + respiratory depression

but clonidine typically also produces:

Marked bradycardia

A negative opioid screen does not exclude an opioid, and a positive response to naloxone does not prove an opioid was taken.

2. Using lack of response to 2 mg naloxone to rule out clonidine responsiveness

Older studies often used relatively small naloxone doses.

Pediatric evidence suggests some patients respond only after:

Much larger naloxone exposure, up to approximately 10 mg

(PubMed⁠)

3. Calling naloxone a reliable antidote

Response remains inconsistent.

Supportive care remains definitive treatment.

4. Intubating every sleepy child before considering naloxone

If:

• Ventilation is adequate
• Airway can be safely supported

a prompt naloxone trial—potentially high-dose with poison-center guidance—may occasionally avoid unnecessary intubation. (PubMed⁠)

Do not delay intubation when ventilation is genuinely inadequate.

5. Treating every bradycardic patient

Clonidine-associated bradycardia is often:

Hemodynamically benign.

Treat the:

• Perfusion
• Blood pressure
• Symptoms

not merely the heart-rate number.

6. Assuming atropine will normalize the heart rate permanently

Atropine may provide only:

Transient or incomplete improvement.

(PubMed⁠)

7. Treating transient early hypertension too aggressively

High-dose clonidine can cause:

Hypertension first → hypotension later

Long-acting antihypertensive therapy during the first phase may worsen subsequent shock.

8. Using dopamine automatically

The historical dopamine-first recommendation is outdated.

Use contemporary physiology-driven vasopressor selection.

9. Performing routine gastric lavage

Modern poisoning management does not support routine lavage.

Airway protection and supportive care are much more important.

10. Giving charcoal to a somnolent child

Clonidine can cause rapid CNS depression.

Unprotected airway → no charcoal.

11. Applying the same observation period to IR, ER, and patches

These formulations have different absorption patterns.

Patch and extended-release exposures can require:

Longer observation

than an uncomplicated small immediate-release ingestion.

12. Underestimating patch ingestion

The current largest Catapres-TTS system contains approximately:

9.28 mg clonidine

despite delivering only 0.3 mg/day therapeutically. (DailyMed⁠)

13. Assuming a used patch is safe

It still contains active medication and can poison a child. (DailyMed⁠)

14. Automatically performing whole-bowel irrigation for patch ingestion

WBI may be considered, but:

It is not routine and has no proven outcome benefit.

Use specialist consultation and assess airway/GI contraindications. (PubMed⁠)

15. Forgetting endoscopic retrieval as a possible selected option

A recent case demonstrated successful removal of an intact gastric clonidine patch by upper endoscopy.

This is:

Promising but case-based—not established standard therapy. (Taylor & Francis Online⁠)

16. Dialyzing for toxin removal

Clonidine is poorly cleared by dialysis.

Hemodialysis is not an effective enhanced-elimination strategy.

(DailyMed⁠)

17. Forgetting renal impairment

Severe renal impairment can extend clonidine’s half-life from approximately:

12–16 h → up to ~41 h

(DailyMed⁠)

so prolonged toxicity is more plausible.

18. Forgetting clonidine withdrawal

Abrupt discontinuation after chronic use can cause:

Rebound hypertension + sympathetic hyperactivity

and can itself become dangerous. (DailyMed⁠)

High-Yield Toxicology Pearls

Clonidine = opioid-like toxidrome + bradycardia

Think:

Sleepy + pinpoint pupils + slow pulse

Key points:

• Clonidine is a:
• Central α₂ agonist
• Imidazoline derivative
• Central mechanism:
• ↓ sympathetic outflow
• Classic overdose:
• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression
• Hypothermia
• Early transient hypertension can occur from peripheral α₂ stimulation
• Current formulations include:
• IR tablets 0.1, 0.2, 0.3 mg
• ER clonidine for ADHD
• Transdermal 0.1, 0.2, 0.3 mg/day
• A single:
• 0.1-mg tablet
• can produce symptoms in a small child
• Recent pediatric data suggest:
• <5 μg/kg carries relatively low risk of major hemodynamic toxicity
• But this is not an absolute safe threshold
• Immediate-release symptoms usually begin:
• 30 min–2 h
• Adult bradycardia:
• Median onset ~2.5 h
• Median duration ~20 h
• Main treatment:
• Supportive care
• Airway/ventilation first
• Naloxone:
• Not a specific antidote
• May reverse clonidine CNS depression
• Pediatric data support high-dose trials in selected cases
• Contemporary poison-center approach:
• ~0.1 mg/kg naloxone, max 2 mg/dose
• Repeat rapidly
• Consider escalation to ~10 mg total/high-dose trial with specialist guidance
• Do not delay intubation for refractory apnea/hypoventilation
• Isolated bradycardia often:
• Does not require treatment
• Symptomatic bradycardia:
• Atropine
• Response may be transient
• Hypotension:
• Fluids if appropriate
• Vasopressor if persistent
• Norepinephrine/epinephrine selected by physiology
• Do not automatically use dopamine
• Early hypertension:
• Usually transient
• Avoid long-acting antihypertensives
• No ipecac
• Routine gastric lavage is obsolete
• Single-dose charcoal:
• Selected early significant ingestion only
• Only with intact/protected airway
• Patch ingestion is especially dangerous:
• Current patches contain 3.09–9.28 mg total clonidine
• Patch ingestion:
• WBI may be considered selectively
• Early endoscopic retrieval is an emerging case-based option
• Dermal patch toxicity:
• Remove every patch
• Levels can persist ~8 h and decline over several days
• Used patches still contain active clonidine
• Hemodialysis:
• Poorly effective for removal
• Severe renal failure:
• Half-life may increase to ~41 h
• Abrupt cessation after chronic therapy:
• Rebound hypertension
• Pregnancy category letters are obsolete
• Current human pregnancy data have not identified a consistent major congenital-malformation signal
• Clonidine enters breast milk; monitor exposed infants for:
• Sedation
• Hypotonia
• Poor feeding
• Apnea
• With adequate airway and cardiovascular support:
• Prognosis is generally excellent

I can continue the next chapter in the same modernized toxicology-reference format.